Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT

Mutations in KIT are more frequent in specific melanoma subtypes, and response to KIT inhibition is likely to depend on the identified mutation. A total of 32 patients with metastatic acral or mucosal melanoma were screened for mutations in KIT exons 11, 13 and 17. KIT mutations were found in 38% of...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2010-04, Vol.102 (8), p.1219-1223
Main Authors: HANDOLIAS, D, HAMILTON, A. L, SALEMI, R, TAN, A, MOODIE, K, KERR, L, DOBROVIC, A, MCARTHUR, G. A
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic Agents - therapeutic use
Benzamides
Benzenesulfonates - therapeutic use
Biological and medical sciences
Clinical Study
Dermatology
Female
Humans
Imatinib Mesylate
Medical sciences
Melanoma - drug therapy
Melanoma - genetics
Melanoma - pathology
Middle Aged
Mutation
Neoplasm Metastasis
Niacinamide - analogs & derivatives
Phenylurea Compounds
Piperazines - therapeutic use
Proto-Oncogene Proteins c-kit - genetics
Pyridines - therapeutic use
Pyrimidines - therapeutic use
Skin Neoplasms - drug therapy
Skin Neoplasms - genetics
Skin Neoplasms - pathology
Tumors
Tumors of the skin and soft tissue. Premalignant lesions
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mutations in KIT are more frequent in specific melanoma subtypes, and response to KIT inhibition is likely to depend on the identified mutation. A total of 32 patients with metastatic acral or mucosal melanoma were screened for mutations in KIT exons 11, 13 and 17. KIT mutations were found in 38% of mucosal and in 6% of acral melanomas. Three patients were treated with imatinib and one with sorafenib. All four patients responded to treatment, but three have since progressed within the brain. The observed clinical responses support further investigation of KIT inhibitors in metastatic melanoma, selected according to KIT mutation status.
ISSN:0007-0920
1532-1827
DOI:10.1038/sj.bjc.6605635